May 04, 2026
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Mar 05, 2026
Altimmune's pemvidutide received FDA Breakthrough Therapy Designation for MASH treatment, with Phase 3 trial initiation planned for 2026. The company raised $75 million in January 2026 to fund development.
Mar 05, 2026
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
Mar 05, 2026
A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
Mar 01, 2026
Amgen, Celltrion, and Palatin Technologies are advancing obesity drug candidates through clinical development, with trials planned for 2026-2028 targeting liver fat reduction, multiple biological pathways, and rare genetic obesity conditions.
Feb 26, 2026
Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.
Feb 17, 2026
Semaglutide and other GLP-1 receptor agonists demonstrate substantial weight loss effectiveness through appetite regulation and blood sugar control, with clinical studies showing average reductions of 14.9% to 20.9% body weight.
Feb 18, 2026
The European Commission has authorized a new 7.2 mg once-weekly dose of Wegovy (semaglutide) for adults with obesity across all 27 EU member states, following positive opinion from the EMA's scientific committee in December 2025.
Feb 15, 2026
The FDA will consider revoking safety exemptions for ultra-processed foods including corn syrup, while retatrutide, a triple-receptor weight loss drug, advances through phase three clinical trials without yet receiving regulatory approval.
Feb 14, 2026
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
Feb 13, 2026
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.